Moderna to seek emergency authorisation for Covid shot for children younger than six
The Omicron variant of Covid-19 was predominant during Moderna's paediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in two to five-year olds, and 44% effective for children six months to under-two years old.
It said these figures were consistent with the lower effectiveness against Omicron seen in adults who had received two doses of its vaccine.
Moderna's vaccine could be the first authorised shot for children under the age of five in the United States, and many parents of young children have been waiting on a vaccine.
A rival shot made by Pfizer and Germany's BioNTech is authorised for use in children five years and older. Their trial results for two- to four-year olds showed a weaker immune response than in adults, forcing the trial to be extended to test a third dose. Results are expected in April.
Source: Reuters
Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people worldwide every day.
Go to: https://www.reuters.com/Related
Award-winning kidney specialist leads the fight against youth dialysis rates 10 Mar 2025 Viatris fined in Morocco over merger notification, sources say 22 Nov 2024 African drug supply chain gets smarter with IBM-powered AI platform 14 Nov 2024 Leadership shakeup at Moderna ahead of major vaccine rollouts 8 Nov 2024 Legal and regulatory insights into South Africa’s growing medical cannabis market 2 Oct 2024 Morocco reports first Mpox case 13 Sep 2024
